## **Daniel A Thomas**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9805115/publications.pdf

Version: 2024-02-01

all docs

54 3,195 26 53 papers citations h-index g-index

62 62 62 62 3780

times ranked

citing authors

docs citations

#	Article	IF	Citations
1	Development of an intracellular quantitative assay to measure compound binding kinetics. Cell Chemical Biology, 2022, 29, 287-299.e8.	2.5	2
2	A kinetic intra-cellular assay (KICA) to measure quantitative compound binding kinetics within living cells. STAR Protocols, 2022, 3, 101078.	0.5	1
3	Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. Journal of Medicinal Chemistry, 2022, 65, 633-664.	2.9	6
4	Acetylation of the Catalytic Lysine Inhibits Kinase Activity in PI3Kδ. ACS Chemical Biology, 2021, 16, 1644-1653.	1.6	2
5	Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode. Journal of Medicinal Chemistry, 2021, 64, 13780-13792.	2.9	3
6	Kinetic intracellular assay measures compound binding kinetics at intracellular targets within living cells. Future Drug Discovery, 2021, 3, .	0.8	0
7	Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target. Journal of Medicinal Chemistry, 2020, 63, 638-655.	2.9	15
8	Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ. ACS Medicinal Chemistry Letters, 2020, 11, 1386-1391.	1.3	2
9	Left Ventricular Longitudinal Contractility Predicts Acuteâ€onâ€Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. Hepatology Communications, 2019, 3, 340-347.	2.0	26
10	Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI. Therapie, 2019, 74, 459-468.	0.6	5
11	Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP. Journal of the American Chemical Society, 2019, 141, 2703-2712.	6.6	95
12	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatology Communications, 2018, 2, 211-222.	2.0	45
13	Flip angle optimization for balanced SSFP: Cardiac cine imaging following the application of standard extracellular contrast agent (gadobutrol). Journal of Magnetic Resonance Imaging, 2018, 47, 255-261.	1.9	3
14	Incidental Cardiac Findings in Non–Electrocardiogram-gated Thoracic Computed Tomography of Intensive Care Unit Patients: Assessment of Prevalence and Underreporting. Journal of Thoracic Imaging, 2018, 33, 168-175.	0.8	7
15	Selectively Targeting the Kinome-Conserved Lysine of PI3Kl̂ as a General Approach to Covalent Kinase Inhibition. Journal of the American Chemical Society, 2018, 140, 932-939.	6.6	73
16	Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate. Biochemical Journal, 2018, 475, 329-340.	1.7	0
17	From PIM1 to PI3Kδvia GSK3β: Target Hopping through the Kinome. ACS Medicinal Chemistry Letters, 2017, 8, 1093-1098.	1.3	15
18	Interrelations of Epicardial Fat Volume, Left Ventricular T1-Relaxation Times and Myocardial Strain in Hypertensive Patients. Journal of Thoracic Imaging, 2017, 32, 169-175.	0.8	10

#	Article	IF	CITATIONS
19	Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease. Journal of Medicinal Chemistry, 2015, 58, 7381-7399.	2.9	118
20	Changes in hospitalization rates for acute coronary syndrome after a two-phase comprehensive smoking ban. European Journal of Preventive Cardiology, 2014, 21, 1575-1582.	0.8	17
21	Dual-Source Radiofrequency Transmission with Patient-Adaptive Local Radiofrequency Shimming for 3.0-T Cardiac MR Imaging: Initial Experience. Radiology, 2012, 263, 77-85.	3.6	44
22	Discovery and Biochemical Characterization of <i>Plasmodium</i> Thioredoxin Reductase Inhibitors from an Antimalarial Set. Biochemistry, 2012, 51, 4764-4771.	1.2	17
23	French Society of Cardiology guidelines for cardiac rehabilitation in adults. Archives of Cardiovascular Diseases, 2012, 105, 309-328.	0.7	91
24	High-yield production and characterization of biologically active GST-tagged human topoisomerase $\hat{\text{Ill}}\pm$ protein in insect cells for the development of a high-throughput assay. Protein Expression and Purification, 2011, 76, 165-172.	0.6	11
25	Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. Thrombosis and Haemostasis, 2011, 105, 1024-1031.	1.8	4
26	Kinetic Analysis of the Inhibition of Matrix Metalloproteinases: Lessons from the Study of Tissue Inhibitors of Metalloproteinases. Methods in Molecular Biology, 2010, 622, 435-450.	0.4	3
27	Feasibility of outpatient coronary angiography with "ad hoc―angioplasty. Archives of Cardiovascular Diseases, 2008, 101, 383-390.	0.7	5
28	A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics, 2006, 6, 2112-2120.	1.3	45
29	Comparative Value of Tissue Doppler Imaging and M-Mode Color Doppler Mitral Flow Propagation Velocity for the Evaluation of Left Ventricular Filling Pressure. Chest, 2005, 128, 2544-2550.	0.4	36
30	Reactive Oxygen Species-mediated $\hat{l}^2$ -Cleavage of the Prion Protein in the Cellular Response to Oxidative Stress. Journal of Biological Chemistry, 2005, 280, 35914-35921.	1.6	151
31	Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochemical Journal, 2004, 383, 45-51.	1.7	539
32	Early vs Late Administration of Glycoprotein Ilb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2004, 292, 362.	3.8	258
33	Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel. Journal of the American College of Cardiology, 2004, 43, 162-168.	1.2	64
34	Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. Journal of the American College of Cardiology, 2003, 41, 8-14.	1.2	55
35	Prognosis of moderate coronary artery lesions in heart transplant patients. Journal of Heart and Lung Transplantation, 2003, 22, 130-136.	0.3	23
36	A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. Journal of the American College of Cardiology, 2002, 40, 1943-1950.	1.2	115

#	Article	IF	CITATIONS
37	Effect of prior exposure to Chlamydia pneumoniae , Helicobacter pylori , or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or nonâe"q-wave acute myocardial infarction. American Journal of Cardiology, 2000, 86, 379-384.	0.7	45
38	Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. American Journal of Cardiology, 2000, 86, 417-421.	0.7	46
39	Low Molecular Weight Heparin After Mechanical Heart Valve Replacement. Circulation, 2000, 101, 1083-1086.	1.6	156
40	A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. International Journal of Cardiology, 2000, 72, 293-294.	0.8	25
41	The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. Journal of Heart and Lung Transplantation, 2000, 19, 557-565.	0.3	38
42	Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. Journal of the American College of Cardiology, 2000, 36, 110-114.	1.2	127
43	Expiratory flow limitation as a determinant of orthopnea in acute left heart failure. Journal of the American College of Cardiology, 2000, 35, 690-700.	1.2	62
44	Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. American Journal of Cardiology, 1998, 82, 749-755.	0.7	74
45	Early Increase of von Willebrand Factor Predicts Adverse Outcome in Unstable Coronary Artery Disease. Circulation, 1998, 98, 294-299.	1.6	309
46	Indium-111 antimyosin scintigraphy before and after coronary bypass surgery: unexpected preoperative myocardial uptakes. International Journal of Cardiology, 1997, 61, 277-285.	0.8	0
47	Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure. Journal of Applied Physiology, 1996, 81, 2571-2579.	1.2	36
48	Parasympathetic activity in Friedreich's ataxia. American Journal of Cardiology, 1996, 78, 847-850.	0.7	16
49	AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart Valves. Circulation, 1996, 94, 2107-2112.	1.6	184
50	Fibrinogen After Coronary Angioplasty as a Risk Factor for Restenosis. Circulation, 1995, 92, 31-38.	1.6	110
51	Doppler ultrasonography of normal neck veins. Journal of Clinical Ultrasound, 1994, 22, 367-373.	0.4	27
52	Diagnosis of Ventricular Tachycardia Using a Pacemaker Holter Function. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1316-1319.	0.5	4
53	Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization. Journal of the American College of Cardiology, 1994, 24, 1236-1241.	1.2	23
54	Coronary artery vasomotion in cardiac transplant patients with normal coronary angiograms. International Journal of Cardiology, 1993, 40, 155-160.	0.8	2